Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edwin Gumapas

Psychiatry Crystal Lake, IL Medical Doctor

NPI 1033101092 CMS profile 648956

25 S Virginia St, Ste 201, Crystal Lake, IL 60014

Open in the dashboard

General payments

$2,688

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edwin Gumapas of Crystal Lake, IL is reported in the CMS Open Payments database as having received $2,688 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 1
2023 General $380 4
2022 General $268 4
2021 General $901 10
2020 General $15 1
2019 General $1,003 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edwin Gumapas
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Edwin Gumapas were reported at $122. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Edwin Gumapas Psychiatry median Middle half National median
2019 $1,003 $184 $59–$605 $163
2020 $15 $119 $36–$372 $114
2021 $901 $143 $43–$576 $132
2022 $268 $153 $50–$590 $149
2023 $380 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $122 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $651 8 payments
  2. ACADIA Pharmaceuticals Inc $629 7 payments
  3. ITI, Inc. $338 4 payments
  4. Alkermes, Inc. $335 4 payments
  5. Janssen Pharmaceuticals, Inc $221 2 payments
  6. E.R. Squibb & Sons, L.L.C. $122 1 payment
  7. Teva Pharmaceuticals USA, Inc. $122 1 payment
  8. Otsuka America Pharmaceutical, Inc. $122 1 payment
  9. Eisai Inc. $94 1 payment
  10. Avanir Pharmaceuticals, Inc. $39 2 payments
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,623 30 payments
  2. Education $47 1 payment
  3. Travel and Lodging $18 1 payment
Products named General payments · program years 2019–2025
  1. INGREZZA $517 6 payments
  2. CAPLYTA $338 4 payments
  3. ARISTADA Cns $335 4 payments
  4. ARISTADA Cns $335 4 payments
  5. ARISTADA Cns $335 4 payments
  6. ARISTADA Cns $335 4 payments
  7. ARISTADA INITIO $306 3 payments
  8. NUPLAZID Parkinsons Disease Psychosis $272 4 payments
  9. NUPLAZID Pdp $246 2 payments
  10. SPRAVATO $221 2 payments
  11. Other $787 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

10,619

Median for Psychiatry: 574

Drug cost

$428,777

Median for Psychiatry: $27,624

Branded share of claims

4.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 60 $98,891
Austedo Deutetrabenazine Brand 39 $95,936
Invega Sustenna Paliperidone Palmitate Brand 12 $36,490
Rexulti Brexpiprazole Brand 55 $31,869
Clozapine Generic 525 $25,484
Chlorpromazine Hcl Generic 366 $16,573
Risperdal Consta Risperidone Microspheres Brand 11 $14,720
Divalproex Sodium Generic 502 $12,171
Aripiprazole Generic 88 $11,202
Quetiapine Fumarate Generic 1,221 $8,196

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$183,225

Medicare's payments for the services billed

Medicare patients

383

Average age 76

Services billed

1,979

217 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 69%
Alzheimer's or dementia 69%
Diabetes 51%
Chronic kidney disease 35%
Heart failure 34%
Ischemic heart disease 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record